---
title: 'Maintenance therapy with trofosfamide, idarubicin and etoposide in patients
  with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a
  multicentre, open-label, randomised controlled phase 3 trial'
date: '2024-12-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39687431/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241217170900&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Rhabdomyosarcoma and other soft tissue sarcomas (STS) with
  high-risk features are still associated with an unsatisfactory outcome. We evaluated
  the efficacy of oral maintenance therapy added at the end of standard therapy in
  patients with high-risk rhabdomyosarcoma and ...'
disable_comments: true
---
BACKGROUND: Rhabdomyosarcoma and other soft tissue sarcomas (STS) with high-risk features are still associated with an unsatisfactory outcome. We evaluated the efficacy of oral maintenance therapy added at the end of standard therapy in patients with high-risk rhabdomyosarcoma and ...